Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (ENZAMET)
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Sponsor: Astellas Pharma Inc
A PHASE3 clinical study on Prostatic Neoplasms, this trial is ongoing. The trial is conducted by Astellas Pharma Inc and has accumulated 13 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Unknown → Active Not Recruiting
-
Jan 2025 — Mar 2025 [monthly]
Unknown PHASE3
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 8 earlier versions
-
Dec 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
Jan 2021 — Nov 2021 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Inc
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Canadian Cancer Trials Group
- Cancer Trials Ireland
- University of Sydney
For direct contact, visit the study record on ClinicalTrials.gov .